Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate for weight loss in metabolic syndrome
NCT00243984Phase 3Suspended
- Sponsor
- Northeast Ohio Medical University
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity, sponsored by Northeast Ohio Medical University. Primary endpoint: Change in weight at 25 weeks. Started Mar 2005; status: suspended.
02
Drugs
topiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00243984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243984.